Identification of Penexanthone A as a Novel Chemosensitizer to Induce Ferroptosis by Targeting Nrf2 in Human Colorectal Cancer Cells

Author:

Zhao Genshi1,Liu Yanying2,Wei Xia23,Yang Chunxia2,Lu Junfei2,Yan Shihuan2,Ma Xiaolin2,Cheng Xue1,You Zhengliang2,Ding Yue2,Guo Hongwei23ORCID,Su Zhiheng23,Xing Shangping23,Zhu Dan23ORCID

Affiliation:

1. First Clinical Medical College, Guangxi Medical University, Nanning 530021, China

2. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China

3. Guangxi Key Laboratory for Bioactive Molecules Research and Evaluation, Nanning 530021, China

Abstract

Ferroptosis has emerged as a potential mechanism for enhancing the efficacy of chemotherapy in cancer treatment. By suppressing nuclear factor erythroid 2-related factor 2 (Nrf2), cancer cells may lose their ability to counteract the oxidative stress induced by chemotherapy, thereby becoming more susceptible to ferroptosis. In this study, we investigate the potential of penexanthone A (PXA), a xanthone dimer component derived from the endophytic fungus Diaporthe goulteri, obtained from mangrove plant Acanthus ilicifolius, to enhance the therapeutic effect of cisplatin (CDDP) on colorectal cancer (CRC) by inhibiting Nrf2. The present study reported that PXA significantly improved the ability of CDDP to inhibit the activity of and induce apoptosis in CRC cells. Moreover, PXA was found to increase the level of oxidative stress and DNA damage caused by CDDP. In addition, the overexpression of Nrf2 reversed the DNA damage and ferroptosis induced by the combination of PXA and CDDP. In vivo experiments using zebrafish xenograft models demonstrated that PXA enhanced the therapeutic effect of CDDP on CRC. These studies suggest that PXA enhanced the sensitivity of CRC to CDDP and induce ferroptosis by targeting Nrf2 inhibition, indicating that PXA might serve as a novel anticancer drug in combination chemotherapy.

Funder

National Natural Science Foundation of China

Guangxi Key Research and Development Program

Natural Science Foundation of Guangxi Zhuang Autonomous Region

Innovative Team for Traditional Chinese Medicinal Materials Quality of Guangxi

Advanced Innovation Teams and Xinghu Scholars Program of Guangxi Medical University and Guangxi Medical University Student Innovation and Entrepreneurship Training Programme

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3